Organization
Royal Marsden NHS Foundation Trust
18 clinical trials
6 abstracts
Abstract
Lete-cel in patients with synovial sarcoma or myxoid/round cell liposarcoma: Planned interim analysis of the pivotal IGNYTE-ESO trial.Org: Memorial Sloan Kettering Cancer Center, Royal Marsden NHS Foundation Trust, The Christie NHS Foundation Trust and University of Manchester, University of Pittsburgh Medical Center (UPMC), Duke Cancer Institute,
Abstract
Effect of polygenic risk score for clinically significant prostate cancer in a screening program: The BARCODE 1 study results.Org: Institute of Cancer Research and The Royal Marsden NHS Foundation Trust, The Royal Marsden NHS Foundation Trust and Institute of Cancer Research, Institute of Cancer Research, The Institute of Cancer Research, Royal Marsden NHS Foundation Trust,
Abstract
H3B-6545 + palbociclib in patients (pts) with locally advanced/metastatic estrogen receptor-positive (ER+), HER2 negative (–) breast cancer (BC).Org: Royal Marsden NHS Foundation Trust, Saint Luke's Cancer Institute, Florida Cancer Specialists/Sarah Cannon Research Institute, Sarah Cannon Research Institute/Tennessee Oncology, Eisai,
Abstract
Ultra-sensitive ctDNA mutation tracking to identify molecular residual disease and predict relapse in patients with early breast cancer.Org: Breast Cancer Now Toby Robins Research Centre, Institute of Cancer Research, Personalis, Inc., The Breast Cancer Now Toby Robins Research Centre, The Institute of Cancer Research and Ralph Lauren Centre for Breast Cancer Research,
Clinical trial
A Phase I Study to Assess the Tolerability, Safety and Biological Effects of ATR Inhibitor (AZD6738) as a Single Agent and in Combination With Palliative Radiation Therapy in Patients With Solid TumoursStatus: Active (not recruiting), Estimated PCD: 2023-12-30
Clinical trial
Phase I Dose Escalation of pAlliative Radiotherapy With Anti-PD1 Antibody Pembrolizumab in Thoracic TumoursStatus: Completed, Estimated PCD: 2021-08-20
Clinical trial
A Randomised Phase II Study of Zimberelimab Anti-PD1 immunOtherapy +/- Domvanalimab Anti-TIGIT Immunotherapy in Resectable Mismatch Repair Deficient Gastric and Gastro-oesophageal Junctional AdenoCarcinomaStatus: Not yet recruiting, Estimated PCD: 2026-09-01
Abstract
H3B-6545 in women with locally advanced/metastatic estrogen receptor-positive (ER+), HER2 negative (–) breast cancer (BC).Org: Sarah Cannon Research Institute/Tennessee Oncology, Saint Luke's Cancer Institute, Florida Cancer Specialists/Sarah Cannon Research Institute, Royal Marsden NHS Foundation Trust, Lineberger Comprehensive Cancer Center,
Clinical trial
Stereotactic Body Radiotherapy Radiotherapy With Immunotherapy in Early Stage Non-small Cell Lung Cancer: Tolerability and Lung EffectsStatus: Active (not recruiting), Estimated PCD: 2024-08-01
Clinical trial
HyPeR: A Phase 1, Dose Escalation Study of Guadecitabine /ASTX727 in Combination With Pembrolizumab (MK3475) in Patients With Refractory Solid TumoursStatus: Recruiting, Estimated PCD: 2026-09-01
Clinical trial
Single and Combined Modality Trans-Oral Robotic Surgery in Early Oropharyngeal Cancer: Exploring the Impact of Surgical Margins on Local Disease Recurrence: The SCORE StudyStatus: Recruiting, Estimated PCD: 2024-12-01
Clinical trial
Randomised Phase II Study of Induction Fulvestrant and CDK4/6 Inhibition With the Addition of Ipatasertib in Metastatic ER+/HER2- Breast Cancer Patients Without ctDNA SuppressionStatus: Recruiting, Estimated PCD: 2026-09-01
Clinical trial
Phase II Study of ROS1 Targeting With Crizotinib in Advanced E-cadherin Negative, ER Positive Lobular Breast Cancer, Diffuse Gastric Cancer, Triple Negative Lobular Breast Cancer or CDH1-mutated Solid TumoursStatus: Active (not recruiting), Estimated PCD: 2024-07-01
Clinical trial
PAveMenT: Phase Ib Study of Palbociclib and Avelumab in Metastatic AR+ Triple Negative Breast CancerStatus: Recruiting, Estimated PCD: 2025-07-31
Clinical trial
A Phase I Trial of VS-6766 (RO5126766) (a Dual RAF/MEK Inhibitor) Exploring Intermittent, Oral Dosing Regimens in Patients With Solid Tumours or Multiple Myeloma, With an Expansion to Explore Intermittent Dosing in Combination With EverolimusStatus: Recruiting, Estimated PCD: 2024-05-01
Clinical trial
A Multicenter Phase II Non-randomised Trial Assessing the Efficacy of DKN-01 Plus Atezolizumab in Patients With Advanced Mismatch Repair Proficient Oesophagogastric CancerStatus: Recruiting, Estimated PCD: 2024-05-30
Clinical trial
Pembrolizumab and Hypofractionated Stereotactic Radiotherapy in Patients With Malignant Pleural MesotheliomaStatus: Terminated, Estimated PCD: 2023-07-25
Clinical trial
The RESCUE Study: Survival and Functional Outcomes Following Salvage Surgery for RESidual or reCurrent sqUamous cEll Carcinoma of the Head and NeckStatus: Recruiting, Estimated PCD: 2027-08-01
Clinical trial
Exploratory Study of Early Biomarkers Allowing Dynamic Assessment of Response to Treatment in Cancers of the Head and NeckStatus: Recruiting, Estimated PCD: 2026-04-01
Clinical trial
A Randomised Trial of Early Detection of Molecular Relapse With Circulating Tumour DNA Tracking and Treatment With Palbociclib Plus Fulvestrant Versus Standard Endocrine Therapy in Patients With ER Positive HER2 Negative Breast CancerStatus: Recruiting, Estimated PCD: 2027-09-01
Clinical trial
Planning Treatment for Oesophago-gastric Cancer: a Randomised Maintenance Therapy TrialStatus: Recruiting, Estimated PCD: 2025-03-01
Abstract
Patients with EGFR mutant (m) MET-altered NSCLC receiving tepotinib with an EGFR tyrosine kinase inhibitor (TKI): A case series.Org: The University of Texas MD Anderson Cancer Center, Stem Cell Transplantation Rsch, Houston, TX, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf (CIO ABCD), University Hospital of Cologne, China Medical University Hospital, Bhaktivedanta Hospital And Research Centre and School of Consciouness,
Clinical trial
Immunotherapy Sequencing in COlon and REctal CancerStatus: Active (not recruiting), Estimated PCD: 2022-10-21